Selected for Canadian Technology Accelerator Life Sciences Program

Nov 30, 2016

VANCOUVER, British Columbia – November 30, 2016 – Aspect Biosystems Ltd., a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering, is pleased to announce that it has been selected to join the Canadian Technology Accelerator San Francisco (CTA SF) Life Sciences program, run by the Canadian Consulate General in San Francisco/Silicon Valley in partnership with Spire Bioventures. 

“We are excited to join the CTA Life Sciences Program in San Francisco and we look forward to expanding our network and tapping into the resources offered by the program,” said Tamer Mohamed, President and CEO of Aspect Biosystems. 

The Canadian Technology Accelerator (CTA) program of Global Affairs Canada provides Canadian high-growth technology companies with exposure to global markets, partners and investors. The San Francisco Bay Area is an integral part of the global value chain and a world-renowned centre for life sciences. This region is also home to some of the largest and most active life sciences-oriented venture capital firms. The Bay Area accounts for one third of all venture capital investment in the United States. The CTA SF Life Sciences program provides Canadian companies an opportunity to grow in this commercialization hub.  

About Aspect Biosystems

Aspect Biosystems Ltd. is a privately held biotechnology company operating at the leading edge of 3D bioprinting and tissue engineering. The company’s proprietary Lab-on-a-Printer™ platform technology is enabling advances in understanding fundamental biology, disease research, development of novel therapeutics, and regenerative medicine. In addition to its internal programs, Aspect is focused on strategically partnering with pharmaceutical and biotechnology companies, as well as academic researchers, to create physiologically and commercially relevant tissues. These tissues are used to advance and accelerate the discovery and development of new drugs and therapies.  

Back to all